Thermo Fisher announces availability of AcroMetrix Coronavirus 2019 (COVID-19) RNA Control

Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific AcroMetrix Coronavirus 2019 (COVID-19) RNA Control, its latest quality control product to monitor and validate COVID-19 molecular diagnostic tests.

In an effort to combat the recent Coronavirus outbreak, Thermo Fisher designed and developed this control as a synthetic RNA, non-infectious control to help labs validate and monitor COVID-19 molecular diagnostic tests. Taking FDA guidelines into account, the controls were carefully designed at two different concentrations: a low positive control and an ultra-low positive control.

AcroMetrix Coronavirus 2019 (COVID-19) RNA Control is prepared by formulating synthetic RNA transcripts that contain highly unique N, S, E and Orf1ab regions of SARS-CoV-2 (COVID-19) genome into a proprietary buffer. The RNA is ready for reverse transcription, PCR amplification and detection, as appropriate to the test. The kit contains two vials of SARS-CoV-2 specific RNA at the concentration that will result low positive and ultra-low positive in most commonly used Polymerase Chain Reaction (PCR) based Coronavirus 2019 (COVID-19) nucleic acid testing methods.

Our team is committed to providing innovative solutions to support our customers with better diagnostic tools. The AcroMetrix Coronavirus 2019 (COVID-19) RNA Control is a positive control to aid in validating and monitoring COVID-19 diagnostic tests."

Gianluca Pettiti, senior vice president and president, Thermo Fisher's specialty diagnostics business

Thermo Fisher has created an online resource to make it easier to find up-to-date information about its response to the COVID-19 pandemic, including availability of its diagnostic test kits. Please refer to https://corporate.thermofisher.com/us/en/index.html for current news, information and frequently asked questions about COVID-19-related products and services that are vital to researchers, labs, healthcare workers and first responders worldwide.

The AcroMetrix Coronavirus 2019 (COVID-19) RNA Control is available globally as a Research Use Only (RUO) product and is not intended for clinical use.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2023, March 22). Thermo Fisher announces availability of AcroMetrix Coronavirus 2019 (COVID-19) RNA Control. News-Medical. Retrieved on April 26, 2024 from https://www.news-medical.net/news/20200401/Thermo-Fisher-announces-availability-of-AcroMetrix-Coronavirus-2019-(COVID-19)-RNA-Control.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "Thermo Fisher announces availability of AcroMetrix Coronavirus 2019 (COVID-19) RNA Control". News-Medical. 26 April 2024. <https://www.news-medical.net/news/20200401/Thermo-Fisher-announces-availability-of-AcroMetrix-Coronavirus-2019-(COVID-19)-RNA-Control.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "Thermo Fisher announces availability of AcroMetrix Coronavirus 2019 (COVID-19) RNA Control". News-Medical. https://www.news-medical.net/news/20200401/Thermo-Fisher-announces-availability-of-AcroMetrix-Coronavirus-2019-(COVID-19)-RNA-Control.aspx. (accessed April 26, 2024).

  • Harvard

    Thermo Fisher Scientific Inc.. 2023. Thermo Fisher announces availability of AcroMetrix Coronavirus 2019 (COVID-19) RNA Control. News-Medical, viewed 26 April 2024, https://www.news-medical.net/news/20200401/Thermo-Fisher-announces-availability-of-AcroMetrix-Coronavirus-2019-(COVID-19)-RNA-Control.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Thermo Fisher announces construction of new cGMP plasmid DNA manufacturing facility